421 results on '"Comas I"'
Search Results
2. A randomized controlled non-inferiority trial of primary care-based facilitated access to an alcohol reduction website (EFAR Spain)
- Author
-
Pintado, Antonia Leiva, Samitier, Elena Campanera, Keysers, Fernando Ferrer, Casaponsa, Rosa Freixedas, Mora, Marta Poch i, Camós, Rosaura Figueras, Alcobet, Silvia Duran, Lainez, Sonia Martínez, Francás, Susana Sostres, Gracia, Olga Bohera, Mora, José Francisco Doz, Andres, Elena Casajuana, Alonso, Esther Bracero, Bellido, Eulalia Duran, Andres, Eva Casajuana, Alvarez, Almudena, Moron, Nuria Garcia, Vidal, Juan Arenas, Martínez, Rosa Pla, Ligero, Cristina, Igualada, Mercè Ribot, Zamorano, Angels Vicente, Corominas, Carmen Garcia, Pou, Elena Navarro, Miquel, Gloria Ribas, Hipolit, Josep Maria Gifre, del Carmen Martí Martínez, María, Cabezas, Rosa María González, Gonzalez, Davinia Vazquez, Sans, Cristina Bonaventura, Tirado, Gemma Castillo, Ortega, Ana Morillo, Millan, Joana Hernandez, Murillo, Dolors Ylla, Massana, Judit Alsina, Junqué, Carme Codorniu, Rodríguez, Cleofé Mellado, Martí, Nora Yanovksy, Najar, Beatriz Fernandez, Vilaubí, Angel Garcia, Hurtado, Francisco Cortés, Rodriguez, Gemma Capdevila, Clols, Teresa Sayrol, Rivera, Francisco Javier Avila, Olivares, Josep Ramon López, Castelló, M. Isabel López, Figueres, Pilar Flores, Arroyo, Alicia Gómez, Puig, Elisenda Garcia, Gómez, Carme Danta, de la Serra Comas i Antich, M., Vergaz, Manel Vila, Solé Dalfó, Marta R., García, Montserrat Espuga, Mauricio, Silvia Crivillé, Bosch, Anna Santeugini, Gonzalez, Andrea Carolina Berengue, Moreno, Eva María Ramírez, Arnau, Gemma Comas, Massa, Monica Mestres, Gilo, Montserrat Navarro, Muñoz, Rosa Blanca Muñoz, Navarro, Xavier Cantano, Ugarte, María Concepción Lasmarías, Arisa, Carme Anglada, Blancafort, Clara Calvó, Cereto, Carme Comino, Plana, MªCarme Parareda, Vila, Natalia Sabat, Martinez, Olga Navarro, Schoenholzer, Renée Vink, del Mar Sánchez Hernández, María, de las Nieves Vizcay Cruchaga, Maria, Rovira, Elvira Pou, Bacete, Remedios Miralles, Cuffi, Pere Sors i, Mont, M. Isabel Matilla, Vilà, Roser Urpinas, Vilella, Marta Beltran, Ribas, Montse Mendez, Roldan, Pau Montoya, Casals, Mireia Bernat, Belmonte, Iris Alarcón, Orriols, Maite Fernandez, López, Elena Mañes, Baena, M. Montserrat Melé, Herrero, M. Carmen Sánchez, Pujol, Meritxell Ferrer, Roqueta, Esther Boix, Arbeloa, Juan Manuel Mendive, Regàs, Marta Mas, Closa, Núria Plana, Caballeria, Elsa, López-Pelayo, Hugo, Segura, Lidia, Wallace, Paul, Oliveras, Clara, Díaz, Estela, Manthey, Jakob, Baena, Begoña, Colom, Joan, and Gual, Antoni
- Published
- 2021
- Full Text
- View/download PDF
3. El joc és cultura. Les apostes ho són?
- Author
-
COMA, ORIOL COMAS I.
- Published
- 2024
- Full Text
- View/download PDF
4. Dispersion of confined optical phonons in semiconductor nanowires in the framework of acontinuum approach
- Author
-
Camps, F. Comas. I., Marques, G. E., and Studart, Nelson
- Subjects
Condensed Matter - Materials Science - Abstract
Confined optical phonons are discussed for a semiconductor nanowire of the Ge (Si)prototype on the basis of a theory developed some years ago. In the present work this theory is adapted to a non polar material and generalized to the case when the phonon dispersion law involves both linear and quadratic terms in the wave vector. The treatment is considered along the lines of a continuous medium model and leads to a system of coupled differential equations describing oscillations of mixed nature. The nanowire is modelled in the form of an infinite circular cylinder and the solutions of the fundamental equations are found. We are thus led to a description of long wavelength optical phonons, which should show a closer agreement with experimental data and with calculations along atomistic models. The presented theory is applied to the calculation of optical phonons in a Ge nanowire. We have found the dispersion curves for various optical phonon modes. We also normalize the modes and discuss the electron-phonon interaction within the deformation potential approximation., Comment: 8 pages, 4 figures
- Published
- 2006
5. A systematic review of methods for quantifying serum testosterone in patients with prostate cancer who underwent castration
- Author
-
Comas, I., Ferrer, R., Planas, J., Celma, A., Regis, L., and Morote, J.
- Published
- 2018
- Full Text
- View/download PDF
6. A novel strategy based on genomics and specific PCR reveals how a multidrug-resistant Mycobacterium tuberculosis strain became prevalent in Equatorial Guinea 15 years after its emergence
- Author
-
Pérez-Lago, L., Izco, S., Herranz, M., Tudó, G., Carcelén, M., Comas, I., Sierra, O., González-Martín, J., Ruiz-Serrano, M.J., Eyene, J., Bouza, E., and García de Viedma, D.
- Published
- 2017
- Full Text
- View/download PDF
7. Selective pressure by rifampicin modulates mutation rates and evolutionary trajectories of mycobacterial genomes
- Author
-
Cebrián-Sastre, E., primary, Chiner-Oms, A., additional, Torres-Pérez, R., additional, Comas, I., additional, Oliveros, J.C., additional, Blázquez, J., additional, and Castañeda-García, A., additional
- Published
- 2023
- Full Text
- View/download PDF
8. List of Contributors
- Author
-
Abdelbary, M.M.H., primary, Aguileta, G., additional, Alout, H., additional, Andam, C.P., additional, Arenas, M., additional, Azarian, T., additional, Baquero, F., additional, Basset, P., additional, Billmyre, R.B., additional, Biron, D.G., additional, Blanc, D.S., additional, Broset, E., additional, Byrnes, E.J., additional, Castro-Nallar, E., additional, Challagundla, L., additional, Cochran, G., additional, Cohan, F.M., additional, Comas, I., additional, Cornel, A.J., additional, D'arc, M., additional, David, J.-P., additional, Delaporte, E., additional, de Meeûs, T., additional, Djogbénou, L., additional, Dorn, P.L., additional, Dujardin, J.-P., additional, Elliot, E., additional, Etienne, L., additional, Feil, E.J., additional, Fisher, M., additional, Fouchier, R.A.M., additional, Galán, J.C., additional, Gibson, W., additional, Gilabert, A., additional, Giraud, T., additional, Gladieux, P., additional, González-Candelas, F., additional, Gonzalo-Asensio, J., additional, Hanage, W.P., additional, Harpending, H., additional, Heitman, J., additional, Hill, C.A., additional, Holzmuller, P., additional, Hurt, A.C., additional, Justi, S., additional, Kopac, Sarah, additional, Koskella, B., additional, Krafsur, E.S., additional, Labbé, P., additional, Lanzaro, G.C., additional, Lee, Y., additional, Lewis, M.D., additional, Liu, Y.-T., additional, Mahungu, T., additional, Martínez, J.L., additional, Miles, M.A., additional, Milesi, P., additional, Missé, D., additional, Morgan, A.D., additional, Morrison, D.A., additional, Nedelkov, D., additional, Owen, A., additional, Pasteur, N., additional, Peeters, M., additional, Pérez-Losada, M., additional, Polley, S.D., additional, Prugnolle, F., additional, Rasigade, J.-P., additional, Robinson, D.A., additional, Shaw, M.A., additional, Shi, Z., additional, Sutherland, C.J., additional, Tibayrenc, M., additional, van Aerle, R., additional, van der Giezen, M., additional, Van Regenmortel, M.H.V., additional, Vernet, G., additional, Vijaykrishna, D., additional, Wang, L.-F., additional, Weill, M., additional, Wirth, T., additional, and Yeo, M., additional
- Published
- 2017
- Full Text
- View/download PDF
9. The Evolution of Antibiotic Resistance
- Author
-
González-Candelas, F., primary, Comas, I., additional, Martínez, J.L., additional, Galán, J.C., additional, and Baquero, F., additional
- Published
- 2017
- Full Text
- View/download PDF
10. SARS-CoV-2 S protein S:A222V + S:D614G mutant 1-up
- Author
-
Ginex, T., primary, Marco-Marin, C., additional, Wieczor, M., additional, Mata, C.P., additional, Krieger, J., additional, Lopez-Redondo, M.L., additional, Frances-Gomez, C., additional, Ruiz-Rodriguez, P., additional, Melero, R., additional, Sanchez-Sorzano, C.O., additional, Martinez, M., additional, Gougeard, N., additional, Forcada-Nadal, A., additional, Zamora-Caballero, S., additional, Gozalbo-Rovira, R., additional, Sanz-Frasquet, C., additional, Bravo, J., additional, Rubio, V., additional, Marina, A., additional, Geller, R., additional, Comas, I., additional, Gil, C., additional, Coscolla, M., additional, Orozco, M., additional, LLacer, J.L., additional, and Carazo, J.M., additional
- Published
- 2022
- Full Text
- View/download PDF
11. SARS-CoV-2 S protein S:D614G mutant 1-up
- Author
-
Ginex, T., primary, Marco-Marin, C., additional, Wieczor, M., additional, Mata, C.P., additional, Krieger, J., additional, Lopez-Redondo, M.L., additional, Frances-Gomez, C., additional, Ruiz-Rodriguez, P., additional, Melero, R., additional, Sanchez-Sorzano, C.O., additional, Martinez, M., additional, Gougeard, N., additional, Forcada-Nadal, A., additional, Zamora-Caballero, S., additional, Gozalbo-Rovira, R., additional, Sanz-Frasquet, C., additional, Bravo, J., additional, Rubio, V., additional, Marina, A., additional, Geller, R., additional, Comas, I., additional, Gil, C., additional, Coscolla, M., additional, Orozco, M., additional, LLacer, J.L., additional, and Carazo, J.M., additional
- Published
- 2022
- Full Text
- View/download PDF
12. The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis
- Author
-
Walker, TM, Miotto, P, Koser, CU, Fowler, PW, Knaggs, J, Iqbal, Z, Hunt, M, Chindelevitch, L, Farhat, MR, Cirillo, DM, Comas, I, Posey, J, Omar, SV, Peto, TEA, Suresh, A, Uplekar, S, Laurent, S, Colman, RE, Nathanson, C-M, Zignol, M, Walker, AS, Crook, DW, Ismail, N, Rodwell, TC, Walker, TM, Miotto, P, Koser, CU, Fowler, PW, Knaggs, J, Iqbal, Z, Hunt, M, Chindelevitch, L, Farhat, MR, Cirillo, DM, Comas, I, Posey, J, Omar, SV, Peto, TEA, Suresh, A, Uplekar, S, Laurent, S, Colman, RE, Nathanson, C-M, Zignol, M, Walker, AS, Crook, DW, Ismail, N, and Rodwell, TC
- Abstract
BACKGROUND: Molecular diagnostics are considered the most promising route to achieving rapid, universal drug susceptibility testing for Mycobacterium tuberculosiscomplex (MTBC). We aimed to generate a WHO endorsed catalogue of mutations to serve as a global standard for interpreting molecular information for drug resistance prediction. METHODS: A candidate gene approach was used to identify mutations as associated with resistance, or consistent with susceptibility, for 13 WHO endorsed anti-tuberculosis drugs. 38,215 MTBC isolates with paired whole-genome sequencing and phenotypic drug susceptibility testing data were amassed from 45 countries. For each mutation, a contingency table of binary phenotypes and presence or absence of the mutation computed positive predictive value, and Fisher's exact tests generated odds ratios and Benjamini-Hochberg corrected p-values. Mutations were graded as Associated with Resistance if present in at least 5 isolates, if the odds ratio was >1 with a statistically significant corrected p-value, and if the lower bound of the 95% confidence interval on the positive predictive value for phenotypic resistance was >25%. A series of expert rules were applied for final confidence grading of each mutation. FINDINGS: 15,667 associations were computed for 13,211 unique mutations linked to one or more drugs. 1,149/15,667 (7·3%) mutations were classified as associated with phenotypic resistance and 107/15,667 (0·7%) were deemed consistent with susceptibility. For rifampicin, isoniazid, ethambutol, fluoroquinolones, and streptomycin, the mutations' pooled sensitivity was >80%. Specificity was over 95% for all drugs except ethionamide (91·4%), moxifloxacin (91·6%) and ethambutol (93·3%). Only two resistance mutations were classified for bedaquiline, delamanid, clofazimine, and linezolid as prevalence of phenotypic resistance was low for these drugs. INTERPRETATION: This first WHO endorsed catalogue of molecular targets for MTBC drug susceptibility
- Published
- 2022
13. Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty® COVID-19 vaccine in nursing home residents
- Author
-
Albert, Eliseo, primary, Burgos, Javier S., additional, Peiró, Salvador, additional, Salas, Dolores, additional, Vanaclocha, Hermelinda, additional, Giménez, Estela, additional, Limón, Ramón, additional, Alcaraz, María Jesús, additional, Sánchez-Payá, José, additional, Díez-Domingo, Javier, additional, Navarro, David, additional, Burgos, J.S., additional, Meneu de Guillerna, R., additional, Vanaclocha Luna, H., additional, Burks, D.J., additional, Cervantes, A., additional, Comas, I., additional, Díez-Domingo, J., additional, Peiro, S., additional, González-Candelas, F., additional, Ferrer Albiach, C., additional, Hernández-Aguado, I., additional, Oliver Ramírez, N., additional, Sánchez-Payá, J., additional, Vento Torres, M., additional, Zapater Latorre, E., additional, and Navarro, D., additional
- Published
- 2022
- Full Text
- View/download PDF
14. Unravelling the population structure and transmission patterns of Mycobacterium tuberculosis in Mozambique, a high TB/HIV burden country
- Author
-
Saavedra, B., primary, López, M.G., additional, Chiner-Oms, Á., additional, García, A.M., additional, Cancino, I, additional, Torres-Puente, M., additional, Villamayor, L., additional, Madrazo, C., additional, Mambuque, E., additional, Sequera, VG., additional, Respeito, D., additional, Blanco, S., additional, Augusto, O., additional, López-Varela, E., additional, García-Basteiro, AL., additional, and Comas, I., additional
- Published
- 2022
- Full Text
- View/download PDF
15. SARS-CoV-2 adaptive immunity in nursing home residents up to eight months after two doses of the Comirnaty® COVID-19 vaccine
- Author
-
Giménez E, Albert E, Burgos JS, Peiró S, Salas D, Vanaclocha H, Limón R, Alcaraz MJ, Sánchez-Payá J, Díez-Domingo J, Comas I, and Gonzáles-Candelas F
- Subjects
nursing home residents ,SARS-CoV-2-S antibodies ,SARS-CoV-2 ,SARS-CoV-2-S T cells ,Comirnaty® COVID-19 vaccine - Abstract
Burgos JS (General Directorate of Research and Healthcare Supervision, Department of Health, Valencia Government, Valencia, Spain); Meneu de Guillerna R (Vice-President Foundation Research Institute in Public Services, Valencia, Spain); Vanaclocha Luna H (General Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain); Burks DJ (The Prince Felipe Research Center-CIPF-, Valencia, Spain; Cervantes A (INCLIVA Health Research Institute, Valencia, Spain); Comas I (Biomedicine Institute of Valencia, Spanish Research Council (CSIC); Díez-Domingo J (Foundation for the promotion of health and biomedical research of the Valencian Community-FISABIO-, Valencia, Spain); Peiro S (Foundation for the promotion of health and biomedical research of the Valencian Community-FISABIO-, Valencia, Spain); González-Candelas F (CIBER in Epidemiology and Public Health, Spain; Joint Research Unit "Infection and Public Health" FISABIO-University of Valencia, Valencia, Spain; Institute for Integrative Systems Biology (I2SysBio), CSIC-University of Valencia, Valencia, Spain); Ferrer Albiach C (Fundación Hospital Provincial de Castelló); Hernández-Aguado I (University Miguel Hernández, Alicante, Spain); Oliver Ramírez N (DataPop Alliance); Sánchez-Payá J (Preventive Medicine Service, Alicante General and University Hospital, Alicante, Spain; Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain; Vento Torres M (Instituto de Investigación Sanitaria La Fe); Zapater Latorre E (Fundación Hospital General Universitario de València); Navarro D (Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain;Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain).
- Published
- 2022
16. Persistent SARS-CoV-2 infection with repeated clinical recurrence in a patient with common variable immunodeficiency
- Author
-
Cabañero-Navalon MD, Garcia-Bustos V, Ruiz-Rodriguez P, Comas I, Coscollá M, Martinez-Priego L, Todolí J, and Moral PM
- Published
- 2022
17. Spatial and temporal distribution of SARS-CoV-2 diversity circulating in wastewater
- Author
-
Pérez-Cataluña A, Chiner-Oms Á, Cuevas-Ferrando E, Díaz-Reolid A, Falcó I, Randazzo W, Girón-Guzmán I, Allende A, Bracho MA, Comas I, and Sánchez G
- Subjects
Variants of concern ,SARS-CoV-2 ,Variants of interest ,Spike mutations ,Wastewater ,Genome sequencing - Abstract
Wastewater-based epidemiology (WBE) has proven to be an effective tool for epidemiological surveillance of SARS-CoV-2 during the current COVID-19 pandemic. Furthermore, combining WBE together with high-throughput sequencing techniques can be useful for the analysis of SARS-CoV-2 viral diversity present in a given sample. The present study focuses on the genomic analysis of SARS-CoV-2 in 76 sewage samples collected during the three epidemiological waves that occurred in Spain from 14 wastewater treatment plants distributed throughout the country. The results obtained demonstrate that the metagenomic analysis of SARS-CoV-2 in wastewater allows the detection of mutations that define the B.1.1.7 lineage and the ability of the technique to anticipate the detection of certain mutations before they are detected in clinical samples. The study proves the usefulness of sewage sequencing to track Variants of Concern that can complement clinical testing to help in decision-making and in the analysis of the evolution of the pandemic.
- Published
- 2022
18. SARS-CoV-2 adaptive immunity in nursing home residents following a third dose of the Comirnaty COVID-19 vaccine
- Author
-
Gimenez E, Albert E, Zulaica J, Torres I, Rusu L, Rodriguez Moreno A, Burgos J, Peiro S, Salas D, Vanaclocha H, Limon R, Alcaraz M, Sanchez-Paya J, Diez-Domingo J, Comas I, Gonzales-Candelas F, Geller R, Navarro D, and Valencian vaccine research program (ProVaVac) study group
- Abstract
A third Comirnaty vaccine dose increased SARS-CoV-2-receptor binding domain antibody levels (median of 93-fold) and neutralizing antibody titers against Wuhan-Hu-1 (median, 57-fold), Beta (median, 22-fold), Delta, (median, 43-fold) and Omicron (median, 8-fold) variants, particularly in SARS-CoV-2-naive individuals, but had a negligible impact on S-reactive T-cell immunity in nursing home residents. © The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
- Published
- 2022
19. SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at midterm after Comirnaty (R) COVID-19 vaccination
- Author
-
Torres I, Bellido-Blasco J, Gimeno C, Burgos J, Albert E, Moya-Malo R, Gasco-Laborda J, Tornero A, Soriano J, Meseguer-Ferrer N, Martinez-Serrano M, Ortiz-Rambla J, Buj H, Hernandez N, Peiro S, Salas D, Limon R, Vanaclocha H, Sanchez-Paya J, Diez-Domingo J, Comas I, Gonzalez-Candelas F, and Navarro D
- Subjects
nursing home residents ,SARS-CoV-2 Delta variant ,breakthrough infection ,Comirnaty (R) COVID-19 vaccine ,spike-reactive T cells ,anti-spike antibodies - Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant breakthrough infections in nursing home residents following vaccination with Comirnaty (R) COVID-19 vaccine were characterized. In total, 201 participants (median age, 87 years; range, 64-100; 133 female) from two nursing homes in the Valencian community (Spain) were included. SARS-CoV-2-Spike (S) antibody responses were determined by a lateral flow immunocromatography (LFIC) assay and by quantitative electrochemiluminescent assay in LFIC-negative participants. SARS-CoV-2-S-IFN gamma T cells were enumerated by flow cytometry in 10 participants. Nasopharyngeal SARS-CoV-2 RNA loads were quantified by real-time polymerase chain reaction assays. Vaccine breakthrough COVID-19 due to the Delta variant occurred in 39 residents (median age, 87 years; range, 69-96; 31 female) at a median of 6.5 months after vaccination (nine requiring hospitalization). Breakthrough infections occurred at a higher rate (p < 0.0001) in residents who had not been previously infected with SARS-CoV-2 (naive) (33/108; 18%) than in those with prior diagnosis of SARS-CoV-2 infection (experienced) (6/93; 6.4%), and were more likely (p < 0.0001) to develop in residents who tested negative by LFIC (20/49) at 3 months after vaccination as compared to their LFIC-positive counterparts (19/142). Among LFIC-negative residents, a trend towards lower plasma anti-RBD antibody levels was noticed in those developing breakthrough infection (p = 0.16). SARS-CoV-2 RNA loads in nasopharyngeal specimens were lower in SARS-CoV-2-experienced residents (p < 0.001) and in those testing positive by LFIC (p = 0.13). The frequency of SARS-CoV-2-S-reactive T cells at 3 months was similar in LFIC-negative residents with (n = 7) or without (n = 3) breakthrough infection. Prior history of SARS-CoV-2 infection and detection of S-reactive antibodies by LFIC at 3 months is associated with a lower risk of Delta-variant breakthrough infection in nursing home residents at midterm after Comirnaty (R) COVID-19 vaccination.
- Published
- 2022
20. Plots of all pN/pS trajectories calculated
- Author
-
Chiner-Oms, Alvaro, L��pez, Mariana G., Moreno-Molina, Miguel, Furi��, Victoria, and Comas, I��aki
- Abstract
Plots of all pN, pS and pN/pS trajectories calculated for the complete MTBC genome, for the antigen-epitope pairs (MTBC wide) and also for the antigen-epitope pairs but splitted by the main MTBC phylogenetic lineages (L1, L2, L3, L4, L5, L6, L7 and the animal-adapted strains). This dataset correspond to Dataset S7 in the publication Gene Evolutionary Trajectories in M. tuberculosis Reveal Temporal Signs of Selection, accepted in PNAS in february 2022.
- Published
- 2022
- Full Text
- View/download PDF
21. Cumulative incidence of SARS-CoV-2 infection in the general population of the Valencian Community (Spain) after the surge of the Omicron BA.1 variant
- Author
-
Camacho J, Giménez E, Albert E, Zulaica J, Álvarez-Rodríguez B, Torres I, Rusu L, Burgos JS, Peiró S, Vanaclocha H, Limón R, Alcaraz MJ, Sánchez-Payá J, Díez-Domingo J, Comas I, Gonzáles-Candelas F, Geller R, and Navarro D
- Subjects
seroprevalence ,SARS-CoV-2 ,T cells ,cumulative incidence of SARS-CoV-2 infection ,neutralizing antibodies - Abstract
Studies investigating the cumulative incidence of and immune status against SARS-CoV-2 infection provide valuable information for shaping public health decision-making. A cross-sectional study on 935 participants, conducted in the Valencian Community (VC), measuring anti-SARS-CoV-2-Receptor Binding Domain-RBD-total antibodies and anti-Nucleocapsid (N)-IgGs via electrochemiluminescence assays. Quantitation of neutralizing antibodies (NtAb) against ancestral and Omicron BA.1 and BA.2 variants and enumeration of SARS-CoV-2-S specific-IFN?-producing CD4(+) and CD8(+) T cells was performed in 100 and 137 participants, respectively. The weighted cumulative incidence was 51.9% (95% CI: 48.7-55.1) and was inversely related to age. Anti-RBD total antibodies were detected in 97% of participants; vaccinated and SARS-CoV-2-experienced (VAC-ex; n=442) presented higher levels (P
- Published
- 2022
22. SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty (R) COVID-19 vaccine: Looking for correlates of protection
- Author
-
Torres I, Gimenez E, Albert E, Zulaica J, Alvarez-Rodriguez B, Burgos J, Peiro S, Limon R, Vanaclocha H, Rodado C, Botija P, Sifre A, Tur B, Lozano R, Orosa I, Vicente-Ruiz M, Carrion R, Clari M, Sanchez-Paya J, Diez-Domingo J, Comas I, Gonzalez-Candelas F, Geller R, and Navarro D
- Subjects
nursing home residents ,breakthrough infection ,neutralizing antibodies ,SARS-CoV-2 Omicron variant ,Comirnaty (R) COVID-19 vaccine ,spike-reactive T cells ,anti-spike antibodies - Abstract
We investigated whether peripheral blood levels of SARS-CoV-2 Spike (5) receptor binding domain antibodies (anti-RBD), neutralizing antibodies (NtAb) targeting Omicron S, and S-reactive-interferon (IFN)-gamma-producing CD4(+) and CD8(+) T cells measured after a homologous booster dose (3D) with the Comirnaty (R) vaccine was associated with the likelihood of subsequent breakthrough infections due to the Omicron variant. An observational study including 146 nursing home residents (median age, 80 years; range, 66-99; 109 female) evaluated for an immunological response after 3D (at a median of 16 days). Anti-RBD total antibodies were measured by chemiluminescent immunoassay. NtAb were quantified by an Omicron S pseudotyped virus neutralization assay. SARS-CoV-2-S specific-IFN gamma-producing CD4(+) and CD8(+) T cells were enumerated by whole-blood flow cytometry for intracellular cytokine staining. In total, 33/146 participants contracted breakthrough Omicron infection (symptomatic in 30/33) within 4 months after 3D. Anti-RBD antibody levels were comparable in infected and uninfected participants (21 123 vs. 24 723 BAU/ml; p = 0.34). Likewise, NtAb titers (reciprocal IC50 titer, 157 vs. 95; p = 0.32) and frequency of virus-reactive CD4(+) (p = 0.82) and CD8(+) (p = 0.91) T cells were similar across participants in both groups. anti-RBD antibody levels and NtAb titers estimated at around the time of infection were also comparable (3445 vs. 4345 BAU/ml; p = 0.59 and 188.5 vs. 88.9; p = 0.70, respectively). Having detectable NtAb against Omicron or SARS-CoV-2-S-reactive-IFN gamma-producing CD4(+) or CD8(+) T cells after 3D was not correlated with increased protection from breakthrough infection (OR, 1.50; p = 0.54; OR, 0.0; p = 0.99 and OR 3.70; p = 0.23, respectively). None of the immune parameters evaluated herein, including NtAb titers against the Omicron variant, may reliably predict at the individual level the risk of contracting COVID-19 due to the Omicron variant in nursing home residents.
- Published
- 2022
23. Fine-grain population structure and transmission patterns of Mycobacterium tuberculosis in southern Mozambique, a high TB/HIV burden area
- Author
-
Saavedra Cervera B, López MG, Chiner-Oms Á, García AM, Cancino-Muñoz I, Torres-Puente M, Villamayor L, Madrazo-Moya C, Mambuque E, Sequera GV, Respeito D, Blanco S, Augusto O, López-Varela E, García-Basteiro AL, and Comas I
- Subjects
tuberculosis ,genomics ,transmission ,Mycobacterium tuberculosis ,molecular epidemiology - Abstract
Genomic studies of the Mycobacterium tuberculosis complex (MTBC) might shed light on the dynamics of its transmission, especially in high-burden settings, where recent outbreaks are embedded in the complex natural history of the disease. To this end, we conducted a 1 year prospective surveillance-based study in Mozambique. We applied whole-genome sequencing (WGS) to 295 positive cultures. We fully characterized MTBC isolates by phylogenetics and dating evaluation, and carried out a molecular epidemiology analysis to investigate further associations with pre-defined transmission risk factors. The majority of strains (49.5%, 136/275) belonged to lineage (L) 4; 57.8 % of them (159/275) were in genomic transmission clusters (cut-off 5 SNPs), and a strikingly high proportion (45.5%) shared an identical genotype (0 SNP pairwise distance). We found two 'likely endemic' clades, comprising 67 strains, belonging to L1.2, which dated back to the late 19th century and were associated with recent spread among people living with human immunodeficiency virus (PLHIV). We describe for the first time the population structure of MTBC in our region, a high tuberculosis (TB)/HIV burden area. Clustering analysis revealed an unforeseen pattern of spread and high rates of progression to active TB, suggesting weaknesses in TB control activities. The long-term presence of local strains in Mozambique, which were responsible for large transmission among HIV/TB-coinfected patients, calls into question the role of HIV in TB transmission.
- Published
- 2022
24. Severe Acute Respiratory Syndrome Coronavirus 2 Adaptive Immunity in Nursing Home Residents Following a Third Dose of the Comirnaty Coronavirus Disease 2019 Vaccine
- Author
-
Giménez E, Albert E, Zulaica J, Torres I, Rusu L, Rodríguez Moreno A, Burgos JS, Peiró S, Salas D, Vanaclocha H, Limón R, Alcaraz MJ, Sánchez-Payá J, Díez-Domingo J, Comas I, Gonzáles-Candelas F, Geller R, and Navarro D
- Subjects
nursing home residents ,SARS-CoV-2-S antibodies ,SARS-CoV-2-S T cells ,Comirnaty COVID-19 vaccine third dose ,neutralizing antibodies - Abstract
A third Comirnaty vaccine dose increased severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain antibody levels (median, 93-fold) and neutralizing antibody titers against Wuhan-Hu-1 (median, 57-fold), Beta (me 22-fold), Delta, (median, 43-fold), and Omicron (median, 8-fold) variants, but had less impact on S-reactive T-cell immunity in nursing home residents.
- Published
- 2022
25. Un plomo con doble inscripción ibérica localizado en Baetulo (Badalona)
- Author
-
Montserrat Comas i Solà, Pepita Padrós i Martí, and Javier Velaza Frías
- Subjects
Linguistics and Language ,Archeology ,History ,Language and Linguistics - Published
- 2019
26. A randomized controlled non-inferiority trial of primary care-based facilitated access to an alcohol reduction website (EFAR Spain)
- Author
-
Caballeria, Elsa, primary, López-Pelayo, Hugo, additional, Segura, Lidia, additional, Wallace, Paul, additional, Oliveras, Clara, additional, Díaz, Estela, additional, Manthey, Jakob, additional, Baena, Begoña, additional, Colom, Joan, additional, Gual, Antoni, additional, Pintado, Antonia Leiva, additional, Samitier, Elena Campanera, additional, Keysers, Fernando Ferrer, additional, Casaponsa, Rosa Freixedas, additional, Mora, Marta Poch i, additional, Camós, Rosaura Figueras, additional, Alcobet, Silvia Duran, additional, Lainez, Sonia Martínez, additional, Francás, Susana Sostres, additional, Gracia, Olga Bohera, additional, Mora, José Francisco Doz, additional, Andres, Elena Casajuana, additional, Alonso, Esther Bracero, additional, Bellido, Eulalia Duran, additional, Andres, Eva Casajuana, additional, Alvarez, Almudena, additional, Moron, Nuria Garcia, additional, Vidal, Juan Arenas, additional, Martínez, Rosa Pla, additional, Ligero, Cristina, additional, Igualada, Mercè Ribot, additional, Zamorano, Angels Vicente, additional, Corominas, Carmen Garcia, additional, Pou, Elena Navarro, additional, Miquel, Gloria Ribas, additional, Hipolit, Josep Maria Gifre, additional, del Carmen Martí Martínez, María, additional, Cabezas, Rosa María González, additional, Gonzalez, Davinia Vazquez, additional, Sans, Cristina Bonaventura, additional, Tirado, Gemma Castillo, additional, Ortega, Ana Morillo, additional, Millan, Joana Hernandez, additional, Murillo, Dolors Ylla, additional, Massana, Judit Alsina, additional, Junqué, Carme Codorniu, additional, Rodríguez, Cleofé Mellado, additional, Martí, Nora Yanovksy, additional, Najar, Beatriz Fernandez, additional, Vilaubí, Angel Garcia, additional, Hurtado, Francisco Cortés, additional, Rodriguez, Gemma Capdevila, additional, Clols, Teresa Sayrol, additional, Rivera, Francisco Javier Avila, additional, Olivares, Josep Ramon López, additional, Castelló, M. Isabel López, additional, Figueres, Pilar Flores, additional, Arroyo, Alicia Gómez, additional, Puig, Elisenda Garcia, additional, Gómez, Carme Danta, additional, de la Serra Comas i Antich, M., additional, Vergaz, Manel Vila, additional, Solé Dalfó, Marta R., additional, García, Montserrat Espuga, additional, Mauricio, Silvia Crivillé, additional, Bosch, Anna Santeugini, additional, Gonzalez, Andrea Carolina Berengue, additional, Moreno, Eva María Ramírez, additional, Arnau, Gemma Comas, additional, Massa, Monica Mestres, additional, Gilo, Montserrat Navarro, additional, Muñoz, Rosa Blanca Muñoz, additional, Navarro, Xavier Cantano, additional, Ugarte, María Concepción Lasmarías, additional, Arisa, Carme Anglada, additional, Blancafort, Clara Calvó, additional, Cereto, Carme Comino, additional, Plana, MªCarme Parareda, additional, Vila, Natalia Sabat, additional, Martinez, Olga Navarro, additional, Schoenholzer, Renée Vink, additional, del Mar Sánchez Hernández, María, additional, de las Nieves Vizcay Cruchaga, Maria, additional, Rovira, Elvira Pou, additional, Bacete, Remedios Miralles, additional, Cuffi, Pere Sors i, additional, Mont, M. Isabel Matilla, additional, Vilà, Roser Urpinas, additional, Vilella, Marta Beltran, additional, Ribas, Montse Mendez, additional, Roldan, Pau Montoya, additional, Casals, Mireia Bernat, additional, Belmonte, Iris Alarcón, additional, Orriols, Maite Fernandez, additional, López, Elena Mañes, additional, Baena, M. Montserrat Melé, additional, Herrero, M. Carmen Sánchez, additional, Pujol, Meritxell Ferrer, additional, Roqueta, Esther Boix, additional, Arbeloa, Juan Manuel Mendive, additional, Regàs, Marta Mas, additional, and Closa, Núria Plana, additional
- Published
- 2021
- Full Text
- View/download PDF
27. Space-time Analysis (1956-2004) of human use and management of the Beach-Dune Systems of Menorca (Balearic Islands, Spain)
- Author
-
Munar, F. X. Roig i, Martín-Prieto, J.A., Lamarca, E. Comas i, and Rodríguez-Perea, A.
- Published
- 2006
28. Una adroguera barcelonina del segle XV: Isabel, vídua de Genís Solsona: Sessió 2: Dones i vida quotidiana
- Author
-
Comas i Via, Mireia
- Published
- 2021
29. A randomized controlled non-inferiority trial of primary care-based facilitated access to an alcohol reduction website (EFAR Spain)
- Author
-
Lidia Segura, Josep Ramon López Olivares, María del Carmen Martí Martínez, Cristina Ligero, Rosa María González Cabezas, Juan Manuel Mendive Arbeloa, Natalia Sabat Vila, Marta R. Solé Dalfó, Renée Vink Schoenholzer, Antonia Leiva Pintado, MªCarme Parareda Plana, Eva María Ramírez Moreno, Olga Bohera Gracia, Marta Poch i Mora, Montserrat Espuga García, Almudena Alvarez, Manel Vila Vergaz, Paul K. Wallace, Gemma Comas Arnau, Montserrat Navarro Gilo, Nora Yanovksy Martí, Carme Danta Gómez, Sonia Martínez Lainez, Estela Díaz, Antoni Gual, Iris Alarcón Belmonte, José Francisco Doz Mora, Ana Morillo Ortega, Fernando Ferrer Keysers, Gemma Castillo Tirado, Susana Sostres Francás, María del Mar Sánchez Hernández, Francisco Cortés Hurtado, Silvia Crivillé Mauricio, Pere Sors i Cuffi, Mercè Ribot Igualada, M. Isabel Matilla Mont, Begoña Baena, Esther Bracero Alonso, Olga Navarro Martinez, Clara Calvó Blancafort, Angels Vicente Zamorano, Marta Beltran Vilella, M. Carmen Sánchez Herrero, Meritxell Ferrer Pujol, Rosa Blanca Muñoz Muñoz, M. Isabel López Castelló, Rosa Pla Martínez, Nuria Garcia Moron, Monica Mestres Massa, Elena Navarro Pou, Josep Maria Gifre Hipolit, Elena Campanera Samitier, Alicia Gómez Arroyo, Esther Boix Roqueta, Jakob Manthey, Elena Casajuana Andres, Rosaura Figueras Camós, Anna Santeugini Bosch, Teresa Sayrol Clols, Hugo López-Pelayo, Mireia Bernat Casals, Clara Oliveras, Angel Garcia Vilaubí, Núria Plana Closa, Carmen Garcia Corominas, Eva Casajuana Andres, Cleofé Mellado Rodríguez, Maite Fernandez Orriols, Marta Mas Regàs, Remedios Miralles Bacete, Carme Anglada Arisa, Juan Arenas Vidal, Montse Mendez Ribas, Silvia Duran Alcobet, Eulalia Duran Bellido, Davinia Vazquez Gonzalez, Xavier Cantano Navarro, Francisco Javier Avila Rivera, Gemma Capdevila Rodriguez, Elena Mañes López, Gloria Ribas Miquel, Elisenda Garcia Puig, Elvira Pou Rovira, Carme Comino Cereto, Carme Codorniu Junqué, Joan Colom, Pilar Flores Figueres, Dolors Ylla Murillo, Joana Hernandez Millan, Roser Urpinas Vilà, M. de la Serra Comas i Antich, Andrea Carolina Berengue Gonzalez, Beatriz Fernandez Najar, Elsa Caballeria, Cristina Bonaventura Sans, Judit Alsina Massana, Maria de las Nieves Vizcay Cruchaga, Pau Montoya Roldan, María Concepción Lasmarías Ugarte, Rosa Freixedas Casaponsa, and M. Montserrat Melé Baena
- Subjects
medicine.medical_specialty ,Alcohol Use Disorders Identification Test ,business.industry ,Confounding ,Psychological intervention ,Health Informatics ,Information technology ,Audit ,T58.5-58.64 ,Missing data ,Full length Article ,BF1-990 ,law.invention ,Risky alcohol use ,Randomized controlled trial ,Screening and brief intervention ,law ,Intervention (counseling) ,Physical therapy ,eHealth ,Psychology ,Medicine ,business ,Primary healthcare - Abstract
Background Brief interventions (BI) for risky drinkers in primary healthcare have been demonstrated to be cost-effective but they are still poorly implemented. Digital BI seems to be a complementary strategy to overcome some barriers to implementation but there is a scarcity of studies in clinical environments. We present the results of a randomized controlled non-inferiority trial which tests the non-inferiority of facilitated access to a digital intervention (experimental condition) for risky drinkers against a face-to-face BI (control condition) provided by primary healthcare professionals. Method In a non-inferiority randomized controlled trial, unselected primary healthcare patients (≥ 18 years old) were given a brief introduction and asked to log on to the study website to fill in the 3-item version of the Alcohol Use Disorders Identification Test. Positively screened patients (4+ for women and 5+ for men) received further online assessment (AUDIT, socio-demographic characteristics and EQ-5D-5L) and were automatically randomized to either face-to-face or digital BI (1:1). The primary outcome was the proportion of patients classified as risky drinkers by the digitally administered AUDIT at month 3. A multiple imputation approach for the missing data was performed. Results Of the 4499 patients approached by 115 healthcare professionals, 1521 completed the AUDIT-C. Of the 368 positively screened patients, 320 agreed to participate and were randomized to either intervention. At month 3, there were more risky drinkers in the experimental group (59.8%) than in the control group (52%), which was similar to the distribution at baseline and less than the pre-specified margin of 10%. The difference was not significant when accounting for possible confounders. Conclusion Digital BI was not inferior to face-to-face BI, in line with previous findings and the a priori hypothesis. However, the low power of the final sample, due to the low recruitment and loss to follow-up, limits the interpretation of the findings. New approaches in this field are required to ensure the effective implementation of digital interventions in actual practice., Highlights • Early identification and Brief Intervention is a cost-effective approach to risky drinkers in primary healthcare. • In our trial, digital Brief Intervention was not inferior to face-to-face Brief Intervention. • Several barriers hinder the engagement with Digital Brief Interventions. • New approaches in this field are required to ensure the effective implementation of digital intervention in real practices.
- Published
- 2021
30. Productores y mercatores de Baetulo (Badalona).
- Author
-
Solà, Montserrat Comas i, primary and Ferreras, Verònica Martínez, additional
- Published
- 2015
- Full Text
- View/download PDF
31. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance
- Author
-
Rodwell, T, Miotto, P, Köser, C, Walker, T, Fowler, PW, Knaggs, J, Iqbal, Z, Hunt, M, Chindelevitch, L, Farhat, M, Cirillo, D, Crook, D, Comas, I, Posey, J, Vally Omar, S, Peto, T, Walker, A, Suresh, A, Uplekar, S, Laurent, S, and Colman, R
- Abstract
Of the 10 million people estimated to have fallen ill with tuberculosis (TB) in 2019, nearly half million developed TB resistant to rifampicin (RIF), and over one million developed TB susceptible to RIF but resistant to isoniazid (INH). Drug resistance must be detected rapidly and accurately to initiate appropriate and effective treatment. The detection of RIF resistance has improved significantly in the past decade with the introduction of rapid diagnostic tools based on DNA detection. The introduction of these tests has dramatically increased the number of TB patients tested for RIF resistance, leading to a 129% increase of individuals started on second-line TB treatment between 2012 and 2019. The majority of patients with RIF-resistant TB can be detected by analysing the 81-base pair fragment of the rpoB gene region. However, the situation is not that clear for other anti-TB drugs due to the lack of knowledge of how phenotypic resistance is associated with mutations in the Mycobacterium tuberculosis (Mtb) genome. In response to this issue the WHO has developed a catalogue of Mtb mutations in the and their association with phenotypic drug resistance. The catalogue provides a reference standard for the interpretation of mutations conferring resistance to all first-line and a variety of second-line drugs. The report summarises the analysis of over 38,000 isolates with matched data on whole genome sequencing and phenotypic drug susceptibility testing from over 40 countries for 13 anti-TB medicines. It lists over 17,000 mutations, their frequency and association with or not with resistance and includes methods used, mutations identified and summaries of important findings for each drug. Tuberculosis laboratories around the world can use the catalogue as a support in the interpretation of genome sequencing results. The catalogue can also guide the development of new molecular drug susceptibility tests, including next-generation sequencing.
- Published
- 2021
32. Diagnóstico de la arteritis de Takayasu mediante técnicas no invasivas
- Author
-
García Camacho, L., Olea Comas, I., Talegón Meléndez, A., and Castell Monsalve, J.
- Published
- 2009
- Full Text
- View/download PDF
33. The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant
- Author
-
Lopez, MG, Chiner-Oms, A, de Viedma, DG, Ruiz-Rodriguez, P, Bracho, MA, Cancino-Munoz, I, D'Auria, G, de Marco, G, Garcia-Gonzalez, N, Goig, GA, Gomez-Navarro, I, Jimenez-Serrano, S, Martinez-Priego, L, Ruiz-Hueso, P, Ruiz-Roldan, L, Torres-Puente, M, Alberola, J, Albert, E, Zaldumbide, MA, Bea-Escudero, MP, Boga, JA, Bordoy, AE, Canut-Blasco, A, Carvajal, A, Eguiluz, GC, Rodriguez, MLC, Costa-Alcalde, JJ, de Toro, M, Peinado, ID, del Pozo, JL, Duchene, S, Fernandez-Pinero, J, Escriva, BF, Cardona, CG, Galan, VG, Jimenez, NG, Crespo, SH, Herranz, M, Lepe, JA, Lopez-Causape, C, Lopez-Hontangas, JL, Martin, V, Martro, E, Beamonte, AM, Ros, MM, Moreno-Munoz, R, Navarro, D, Navarro-Mari, JM, Not, A, Oliver, A, Palop-Borras, B, Grande, MP, Pedrosa-Corral, I, Gonzalez, MCP, Perez-Lago, L, Perez-Ruiz, M, Vazquez, LP, Rabella, N, Rezusta, A, Fonseca, LR, Sanbonmatsu-Gamez, S, Sicilia, J, Soriano, A, Balaguer, MDT, Torres, I, Tristancho, A, Marimon, JM, Coscolla, M, Gonzalez-Candelas, F, and Comas, I
- Abstract
The coronavirus disease 2019 (COVID-19) pandemic has affected the world radically since 2020. Spain was one of the European countries with the highest incidence during the first wave. As a part of a consortium to monitor and study the evolution of the epidemic, we sequenced 2,170 samples, diagnosed mostly before lockdown measures. Here, we identified at least 500 introductions from multiple international sources and documented the early rise of two dominant Spanish epidemic clades (SECs), probably amplified by superspreading events. Both SECs were related closely to the initial Asian variants of SARS-CoV-2 and spread widely across Spain. We inferred a substantial reduction in the effective reproductive number of both SECs due to public-health interventions (R-e < 1), also reflected in the replacement of SECs by a new variant over the summer of 2020. In summary, we reveal a notable difference in the initial genetic makeup of SARS-CoV-2 in Spain compared with other European countries and show evidence to support the effectiveness of lockdown measures in controlling virus spread, even for the most successful genetic variants. Analysis of 2,170 SARS-CoV-2 sequences from the first wave of the COVID-19 epidemic in Spain provides insights into transmission patterns and the effects of lockdown on the emergence of new variants.
- Published
- 2021
34. Integrative transnational analysis to dissect tuberculosis transmission events along the migratory route from Africa to Europe
- Author
-
Martínez-Lirola M, Jajou R, Mathys V, Martin A, Cabibbe AM, Valera A, Sola-Campoy PJ, Abascal E, Rodríguez-Maus S, Garrido-Cárdenas JA, Bonillo M, Chiner-Oms Á, López B, Vallejo-Godoy S, Comas I, Prof PM, Prof DMC, Soolingen Prof D, Pérez-Lago L, and de Viedma DG
- Subjects
Horn of Africa ,transmission ,Tuberculosis ,trans-national - Abstract
Background: Growing international migration has increased the complexity of tuberculosis transmission patterns. Italy's decision to close its borders in 2018 made of Spain the new European porte entree for migration from the Horn of Africa (HA). In one of the first rescues of migrants from this region at the end of 2018, tuberculosis was diagnosed in eight subjects, mainly unaccompanied minors. Methods: Mycobacterium tuberculosis isolates from these recently arrived migrants were analysed by Mycobacterial Interspersed Repetitive-Unit/Variable-Number of Tandem Repeat (MIRU-VNTR) and subsequent whole genome sequencing (WGS) analysis. Data were compared with those from collections from other European countries receiving migrants from the HA and a strain-specific PCR was applied for a fast searching of common strains. Infections in a cellular model were performed to assess strain virulence. Results: MIRU-VNTR analysis allowed identifying an epidemiological cluster involving three of the eight cases from Somalia (0 single-nucleotide polymorphisms between isolates, HA cluster). Following detailed interviews revealed that two of these cases had shared the same migratory route in most of the trip and had spent a long time at a detention camp in Libya. To confirm potential en route transmission for the three cases, we searched the same strain in collections from other European countries receiving migrants from the HA. MIRU-VNTR, WGS and a strainspecific PCR for the HA strain were applied. The same strain was identified in 12 cases from Eritrea diagnosed soon after their arrival in 2018 to the Netherlands, Belgium and Italy. Intracellular replication rate of the strain did not reveal abnormal virulence. Conclusions: Our study suggests a potential en route transmission of a pan-susceptible strain, which caused at least 15 tuberculosis cases in Somalian and Eritrean migrants diagnosed in four different European countries.
- Published
- 2021
35. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020
- Author
-
Hodcroft, EB, Zuber, M, Nadeau, S, Vaughan, TG, Crawford, KHD, Althaus, CL, Reichmuth, ML, Bowen, JE, Walls, AC, Corti, D, Bloom, JD, Veesler, D, Mateo, D, Hernando, A, Comas, I, Candelas, FG, Stadler, T, Neher, RA, Rabella N., Navarro F., Miró E., Fernandez-Cadenas I, and Parra Grande, Monica
- Abstract
Following its emergence in late 2019, the spread of SARS-CoV-21,2 has been tracked by phylogenetic analysis of viral genome sequences in unprecedented detail(3-5). Although the virus spread globally in early 2020 before borders closed, intercontinental travel has since been greatly reduced. However, travel within Europe resumed in the summer of 2020. Here we report on a SARS-CoV-2 variant, 20E (EU1), that was identified in Spain in early summer 2020 and subsequently spread across Europe. We find no evidence that this variant has increased transmissibility, but instead demonstrate how rising incidence in Spain, resumption of travel, and lack of effective screening and containment may explain the variant's success. Despite travel restrictions, we estimate that 20E (EU1) was introduced hundreds of times to European countries by summertime travellers, which is likely to have undermined local efforts to minimize infection with SARS-CoV-2. Our results illustrate how a variant can rapidly become dominant even in the absence of a substantial transmission advantage in favourable epidemiological settings. Genomic surveillance is critical for understanding how travel can affect transmission of SARS-CoV-2, and thus for informing future containment strategies as travel resumes.
- Published
- 2021
36. Overlapping prison/community tuberculosis outbreaks in Costa Rica revealed by alternative analysis of suboptimal material
- Author
-
Jbara S, Herranz M, Sola-Campoy PJ, Rodríguez-Grande C, Chiner-Oms Á, Comas I, Muñoz P, García de Viedma D, and Pérez-Lago L
- Subjects
low quality DNA ,outbreak ,tuberculosis ,surveillance ,epidemiology ,prisons - Abstract
Costa Rica has a low incidence of tuberculosis. Thus, identifying transmission hotspots is key to implement interventions. A tuberculosis outbreak was suspected in a prison in Costa Rica. Given the suboptimal quality of the samples received in our laboratory in Madrid, we applied alternative schemes for their analysis. In the first scheme, we bypassed the standard approach of applying systematic mycobacterial interspersed repetitive units-variable number of tandem repeats (MIRU-VNTR) and used a strain-specific polymerase chain reaction (PCR) that allowed identifying a cluster involving six cases (C1). The second scheme followed the canonical MIRU-VNTR path coupled with a whole-genomic amplification step, by which a second unsuspected overlapping cluster (C2), was detected in the same prison. These findings justified the implementation of a surveillance programme adapted to local resources based on a tailored multiplex allele-specific oligonucleotide (ASO)-PCR targeting C1 and C2. Presence of the C2 strain at a different prison was determined. ASO-PCR was applied extensively and alerted to the active circulation of one of the strains within and beyond prisons. Our study shows that alternative methodological strategies may provide useful data in settings with lack of resources for performing systematic standard molecular epidemiology programmes and/or with suboptimal material for analysis.
- Published
- 2021
37. Evolutionary and Phenotypic Characterization of Two Spike Mutations in European Lineage 20E of SARS-CoV-2
- Author
-
Ruiz-Rodriguez, P, Frances-Gomez, C, Chiner-Oms, A, Lopez, MG, Jimenez-Serrano, S, Cancino-Munoz, I, Ruiz-Hueso, P, Torres-Puente, M, Bracho, MA, D'Auria, G, Martinez-Priego, L, Guerreiro, M, Montero-Alonso, M, Gomez, MD, Pinana, JL, Gonzalez-Candelas, F, Comas, I, Marina, A, Geller, R, Coscolla, M, Rabella N., Navarro F., Miró E., and SeqCOVID Spain Consortium
- Subjects
variants ,SARS-CoV-2 ,homoplasy ,adaptive mutations ,antibody escape ,spike ,HR2 - Abstract
We have detected two mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at amino acid positions 1163 and 1167 that appeared independently in multiple transmission clusters and different genetic backgrounds. Furthermore, both mutations appeared together in a cluster of 1,627 sequences belonging to clade 20E. This cluster is characterized by 12 additional single nucleotide polymorphisms but no deletions. The available structural information on the S protein in the pre- and postfusion conformations predicts that both mutations confer rigidity, which could potentially decrease viral fitness. Accordingly, we observed reduced infectivity of this spike genotype relative to the ancestral 20E sequence in vitro, and the levels of viral RNA in nasopharyngeal swabs were not significantly higher. Furthermore, the mutations did not impact thermal stability or antibody neutralization by sera from vaccinated individuals but moderately reduce neutralization by convalescent-phase sera from the early stages of the pandemic. Despite multiple successful appearances of the two spike mutations during the first year of SARS-CoV- 2 evolution, the genotype with both mutations was displaced upon the expansion of the 20I (Alpha) variant. The midterm fate of the genotype investigated was consistent with the lack of advantage observed in the clinical and experimental data. IMPORTANCE We observed repeated, independent emergence of mutations in the SARS-CoV-2 spike involving amino acids 1163 and 1167, within the HR2 functional motif. Conclusions derived from evolutionary and genomic diversity analysis suggest that the co-occurrence of both mutations might pose an advantage for the virus and therefore a threat to effective control of the epidemic. However, biological characterization, including in vitro experiments and analysis of clinical data, indicated no clear benefit in terms of stability or infectivity. In agreement with this, continuous epidemiological surveillance conducted months after the first observations revealed that both mutations did not successfully outcompete other variants and stopped circulating 9 months after their initial detection. Additionally, we evaluated the potential of both mutations to escape neutralizing antibodies, finding that the presence of these two mutations on their own is not likely to confer antibody escape. Our results provide an example of how newly emerged spike mutations can be assessed to better understand the risk posed by new variants and indicate that some spike mutations confer no clear advantage to the virus despite independently emerging multiple times and are eventually displaced by fitter variants.
- Published
- 2021
38. An evolutionary functional genomics approach identifies novel candidate regions involved in isoniazid resistance in Mycobacterium tuberculosis
- Author
-
Furió V, Moreno-Molina M, Chiner-Oms Á, Villamayor LM, Torres-Puente M, and Comas I
- Abstract
Efforts to eradicate tuberculosis are hampered by the rise and spread of antibiotic resistance. Several large-scale projects have aimed to specifically link clinical mutations to resistance phenotypes, but they were limited in both their explanatory and predictive powers. Here, we combine functional genomics and phylogenetic associations using clinical strain genomes to decipher the architecture of isoniazid resistance and search for new resistance determinants. This approach has allowed us to confirm the main target route of the antibiotic, determine the clinical relevance of redox metabolism as an isoniazid resistance mechanism and identify novel candidate genes harboring resistance mutations in strains with previously unexplained isoniazid resistance. This approach can be useful for characterizing how the tuberculosis bacilli acquire resistance to new antibiotics and how to forestall them. Victoria Furio et al. apply functional genomics and evolutionary analyses to the study of antibiotic resistance in tuberculosis. Focusing on isoniazid resistance and using genomic data from clinical strains, they identify novel candidate genes with resistance mutations and further uncover the mechanisms underlying drug resistance.
- Published
- 2021
39. Recurrences of multidrug-resistant tuberculosis: Strains involved, within-host diversity, and fine-tuned allocation of reinfections
- Author
-
Pérez-Lago L, Monteserin J, Paul R, Maus SR, Yokobori N, Herranz M, Sicilia J, Acosta F, Fajardo S, Chiner-Oms Á, Matteo M, Simboli N, Comas I, Muñoz P, López B, Ritacco V, and García de Viedma D
- Subjects
recurrences ,clonal variants ,MDR ,Tuberculosis ,molecular epidemiology ,WGS ,diversity ,reinfection - Abstract
Recurrent tuberculosis occurs due to exogenous reinfection or reactivation/persistence. We analysed 90 sequential MDR Mtb isolates obtained in Argentina from 27 patients with previously diagnosed MDR-TB that recurred in 2018 (1-10 years, 2-10 isolates per patient). Three long-term predominant strains were responsible for 63% of all MDR-TB recurrences. Most of the remaining patients were infected by strains different from each other. Reactivation/persistence of the same strain caused all but one recurrence, which was due to a reinfection with a predominant strain. One of the prevalent strains showed marked stability in the recurrences, while in another strain higher SNP-based diversity was observed. Comparisons of intra- versus inter-patient SNP distances identified two possible reinfections with closely related variants circulating in the community. Our results show a complex scenario of MDR-TB infections in settings with predominant MDR Mtb strains.
- Published
- 2021
40. Complete Analysis of the Epidemiological Scenario around a SARS-CoV-2 Reinfection: Previous Infection Events and Subsequent Transmission
- Author
-
Pérez Lago L, Pérez Latorre L, Herranz M, Tejerina F, Sola-Campoy PJ, Sicilia J, Suárez-González J, Andrés-Zayas C, Chiner-Oms A, Jiménez-Serrano S, García-González N, Comas I, González-Candelas F, Martínez-Laperche C, Catalán P, Muñoz P, and García de Viedma D
- Subjects
SARS-CoV-2 ,transmission ,genomics ,COVID-19 ,reinfection - Abstract
The first descriptions of reinfection by SARS-CoV-2 have been recently reported. However, these studies focus exclusively on the reinfected case, without considering the epidemiological context of the event. Our objectives were to perform a complete analysis of the sequential infections and community transmission events around a SARS-CoV-2 reinfection, including the infection events preceding it, the exposure, and subsequent transmissions. Our analysis was supported by host genetics, viral whole-genome sequencing, phylogenomic viral population analysis, and refined epidemiological data obtained from interviews with the involved subjects. The reinfection involved a 53-year-old woman with asthma (Case A), with a first COVID-19 episode in April 2020 and a much more severe second episode 4-1/2 months later, with SARS-CoV-2 seroconversion in August, that required hospital admission. An extended genomic analysis allowed us to demonstrate that the strain involved in Case A's reinfection was circulating in the epidemiological context of Case A and was also transmitted subsequently from Case A to her family context. The reinfection was also supported by a phylogenetic analysis, including 348 strains from Madrid, which revealed that the strain involved in the reinfection was circulating by the time Case A suffered the second episode, August-September 2020, but absent at the time range corresponding to Case A's first episode. IMPORTANCE We present the first complete analysis of the epidemiological scenario around a reinfection by SARS-CoV-2, more severe than the first episode, including three cases preceding the reinfection, the reinfected case per se, and the subsequent transmission to another seven cases.
- Published
- 2021
41. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020
- Author
-
Hodcroft E.B., Zuber M., Nadeau S., Vaughan T.G., Crawford K.H.D., Althaus C.L., Reichmuth M.L., Bowen J.E., Walls A.C., Corti D., Bloom J.D., Veesler D., Mateo D., Hernando A., Comas I., González-Candelas F., Goig G.A., Chiner-Oms Á., Cancino-Muñoz I., López M.G., Torres-Puente M., Gomez-Navarro I., Jiménez-Serrano S., Ruiz-Roldán L., Bracho M.A., García-González N., Martínez-Priego L., Galán-Vendrell I., Ruiz-Hueso P., De Marco G., Ferrús M.L., Carbó-Ramírez S., D’Auria G., Coscollá M., Ruiz-Rodríguez P., Roig-Sena F.J., Sanmartín I., Garcia-Souto D., Pequeno-Valtierra A., Tubio J.M.C., Rodríguez-Castro J., Rabella N., Navarro F., Miró E., Rodríguez-Iglesias M., Galán-Sanchez F., Rodriguez-Pallares S., de Toro M., Escudero M.B., Azcona-Gutiérrez J.M., Alberdi M.B., Mayor A., García-Basteiro A.L., Moncunill G., Dobaño C., Cisteró P., García-de-Viedma D., Pérez-Lago L., Herranz M., Sicilia J., Catalán-Alonso P., Muñoz P., Muñoz-Cuevas C., Rodríguez-Rodríguez G., Alberola-Enguidanos J., Nogueira J.M., Camarena J.J., Rezusta A., Tristancho-Baró A., Milagro A., Martínez-Cameo N.F., Gracia-Grataloup Y., Martró E., Bordoy A.E., Not A., Antuori-Torres A., Benito R., Algarate S., Bueno J., del Pozo J.L., Boga J.A., Castelló-Abietar C., Rojo-Alba S., Alvarez-Argüelles M.E., Melon S., Aranzamendi-Zaldumbide M., Vergara-Gómez A., Fernández-Pinero J., Martínez M.J., Vila J., Rubio E., Peiró-Mestres A., Navero-Castillejos J., Posada D., Valverde D., Estévez-Gómez N., Fernandez-Silva I., de Chiara L., Gallego-García P., Varela N., Moreno R., Tirado M.D., Gomez-Pinedo U., Gozalo-Margüello M., Eliecer-Cano M., Méndez-Legaza J.M., Rodríguez-Lozano J., Siller M., Pablo-Marcos D., Oliver A., Reina J., López-Causapé C., Canut-Blasco A., Hernáez-Crespo S., Cordón M.L.A., Lecároz-Agara M.-C., Gómez-González C., Aguirre-Quiñonero A., López-Mirones J.I., Fernández-Torres M., Almela-Ferrer M.R., Gonzalo-Jiménez N., Ruiz-García M.M., Galiana A., Sanchez-Almendro J., Cilla G., Montes M., Piñeiro L., Sorarrain A., Marimón J.M., Gomez-Ruiz M.D., López-Hontangas J.L., González Barberá E.M., Navarro-Marí J.M., Pedrosa-Corral I., Sanbonmatsu-Gámez S., Pérez-González C., Chamizo-López F., Bordes-Benítez A., Navarro D., Albert E., Torres I., Gascón I., Torregrosa-Hetland C.J., Pastor-Boix E., Cascales-Ramos P., Fuster-Escrivá B., Gimeno-Cardona C., Ocete M.D., Medina-Gonzalez R., González-Cantó J., Martínez-Macias O., Palop-Borrás B., de Toro I., Mediavilla-Gradolph M.C., Pérez-Ruiz M., González-Recio Ó., Gutiérrez-Rivas M., Simarro-Córdoba E., Lozano-Serra J., Robles-Fonseca L., de Salazar A., Viñuela-González L., Chueca N., García F., Gómez-Camarasa C., Carvajal A., de la Puente R., Martín-Sánchez V., Fregeneda-Grandes J.-M., Molina A.J., Argüello H., Fernández-Villa T., Farga-Martí M.A., Domínguez-Márquez V., Costa-Alcalde J.J., Trastoy R., Barbeito-Castiñeiras G., Coira A., Pérez-del-Molino M.L., Aguilera A., Planas A.M., Soriano A., Fernandez-Cádenas I., Pérez-Tur J., Marcos M.Á., Moreno-Docón A., Viedma E., Mingorance J., Galán-Montemayor J.C., Parra-Grande M., Stadler T., Neher R.A., Swiss National Science Foundation, European Commission, University of Basel, ETH Zurich, National Institute of General Medical Sciences (US), National Institute of Allergy and Infectious Diseases (US), Burroughs Wellcome Fund, Instituto de Salud Carlos III, Consejo Superior de Investigaciones Científicas (España), European Research Council, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Howard Hughes Medical Institute, Hodcroft, Emma B. [0000-0002-0078-2212], Zuber, Moira [0000-0002-4275-8739], Nadeau, Sarah [0000-0003-1008-8918], Vaughan, Timothy G. [0000-0001-6220-2239], Crawford, Katharine H. D. [0000-0002-6223-4019], Althaus, Christian L. [0000-0002-5230-6760], Reichmuth, Martina L. [0000-0001-9345-851X], Bowen, John E. [0000-0003-3590-9727], Walls, Alexandra C. [0000-0002-9636-8330], Corti, Davide [0000-0002-5797-1364], Bloom, Jesse D. [0000-0003-1267-3408], Veesler, David [0000-0002-6019-8675], Mateo, David [0000-0002-1590-4163], Hernando de Castro, Alberto [0000-0003-1180-1068], Comas, Iñaki [0000-0001-5504-9408], González-Candelas, Fernando [0000-0002-0879-5798], Stadler, Tanja [0000-0001-6431-535X], Neher, Richard A. [0000-0003-2525-1407], Hodcroft, Emma B., Zuber, Moira, Nadeau, Sarah, Vaughan, Timothy G., Crawford, Katharine H. D., Althaus, Christian L., Reichmuth, Martina L., Bowen, John E., Walls, Alexandra C., Corti, Davide, Bloom, Jesse D., Veesler, David, Mateo, David, Hernando de Castro, Alberto, Comas, Iñaki, González-Candelas, Fernando, Stadler, Tanja, and Neher, Richard A.
- Subjects
Phylogenetics ,Sars-Cov-2 ,Viral infection ,0303 health sciences ,2019-20 coronavirus outbreak ,Multidisciplinary ,Coronavirus disease 2019 (COVID-19) ,SARS-CoV-2 ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,610 Medicine & health ,3. Good health ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Transmission (mechanics) ,Geography ,360 Social problems & social services ,law ,Development economics ,030217 neurology & neurosurgery ,030304 developmental biology - Abstract
Following its emergence in late 2019, the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1,2 has been tracked via phylogenetic analysis of viral genome sequences in unprecedented detail3–5. While the virus spread globally in early 2020 before borders closed, intercontinental travel has since been greatly reduced. However, within Europe travel resumed in the summer of 2020. Here we report on a novel SARS-CoV-2 variant, 20E (EU1), that emerged in Spain in early summer, and subsequently spread across Europe. We find no evidence of increased transmissibility, but instead demonstrate how rising incidence in Spain, resumption of travel, and lack of effective screening and containment may explain the variant’s success. Despite travel restrictions, we estimate 20E (EU1) was introduced hundreds of times to European countries by summertime travelers, likely undermining local efforts to keep SARS-CoV-2 cases low. Our results demonstrate how a variant can rapidly become dominant even in absence of a substantial transmission advantage in favorable epidemiological settings. Genomic surveillance is critical to understanding how travel can impact SARS-CoV-2 transmission, and thus for informing future containment strategies as travel resumes., This work was supported by the Swiss National Science Foundation (SNSF) through grant numbers 31CA30 196046 (to RAN, EBH, CLA), 31CA30 196267 (to TS), European Union’s Horizon 2020 research and innovation programme - project EpiPose (No 101003688) (MLR, CLA), core funding by the University of Basel and ETH Zürich, the National Institute of General Medical Sciences (R01GM120553 to DV), the National Institute of Allergy and Infectious Diseases (DP1AI158186 and HHSN272201700059C to DV), a Pew Biomedical Scholars Award (DV), an Investigators in the Pathogenesis of Infectious Disease Awards from the Burroughs Wellcome Fund (DV and JDB), a Fast Grants (DV), and NIAID grants R01AI141707 (JDB) and F30AI149928 (KHDC). SeqCOVID-SPAIN is funded by the Instituto de Salud Carlos III project COV20/00140, Spanish National Research Council and ERC StG 638553 to IC and BFU2017-89594R from MICIN to FGC. JDB is an Investigator of the Howard Hughes Medical Institute.
- Published
- 2021
- Full Text
- View/download PDF
42. Whole genomic sequencing based genotyping reveals a specific X3 sublineage restricted to Mexico and related with multidrug resistance
- Author
-
Jiménez-Ruano AC, Madrazo-Moya CF, Cancino-Muñoz I, Mejía-Ponce PM, Licona-Cassani C, Comas I, Muñiz-Salazar R, and Zenteno-Cuevas R
- Abstract
Whole genome sequencing (WGS) has been shown to be superior to traditional procedures of genotyping in tuberculosis (TB), nevertheless, reports of its use in drug resistant TB (DR-TB) isolates circulating in Mexico, are practically unknown. Considering the above the main of this work was to identify and characterize the lineages and genomic transmission clusters present in 67 DR-TB isolates circulating in southeastern Mexico. The results show the presence of three major lineages: L1 (3%), L2 (3%) and L4 (94%), the last one included 16 sublineages. Sublineage 4.1.1.3 (X3) was predominant in 18 (27%) of the isolates, including one genomic cluster, formed by eleven multidrug resistant isolates and sharing the SIT 3278, which seems to be restricted to Mexico. By the use of WGS, it was possible to identify the high prevalence of L4 and a high number of sublineages circulating in the region, also was recognized the presence of a novel X3 sublineage, formed exclusively by multidrug resistant isolates and with restrictive circulation in Mexico for at least the past 17 years.
- Published
- 2021
43. Urbamedia, un sistema d'informació geogràfica per analitzar la ciutat de Girona
- Author
-
Comas i Vila, David
- Subjects
Bases de donnés géographiques ,Hypertext ,City ,Girona ,Hipertexto ,Bases de dades geogràfiques ,Bases de datos geográficos ,Key concepts ,Ciutat ,Ciudad ,SIG ,Ville ,Gerona ,Concepts clé ,Geographic database ,Gérone ,Conceptes clau ,Hipertext ,Conceptos clave - Published
- 2021
44. Proper assignation of reactivation in a COVID-19 recurrence initially interpreted as a reinfection
- Author
-
Pérez Lago L, Martínez Lozano H, Pajares Díaz JA, Díaz Gómez A, Machado M, Sola-Campoy PJ, Herranz M, Buenestado-Serrano S, Valerio M, Olmedo M, Andrés Zayas C, Comas I, González Candelas F, Bañares R, Catalán P, Muñoz P, García de Viedma D, and Gregorio Marañón Microbiology-ID COVID-19 Study Group
- Subjects
reactivation ,SARS-CoV-2 ,nosocomial transmission ,COVID-19 ,WGS - Abstract
A 77-year-old-male (Case R) who had had a previous diagnosis of mild COVID-19 episode, was hospitalized 35 days later. On Day 23 post-admission, he developed a second COVID-19 episode, now severe, and finally died. Initially, Case R COVID-19 recurrence was interpreted as a reinfection due to the exposure to a SARS-CoV-2 RT-PCR-positive room-mate. However, whole-genome-sequencing indicated that case R recurrence corresponded to a reactivation of the strain involved in his first episode. Case R reactivation had major consequences, leading to a more severe episode, and causing a subsequent transmission to another two hospitalized patients, one of them with fatal outcome.
- Published
- 2021
45. Epidemiological, clinical and genomic snapshot of the first 100 B.1.1.7 SARS-CoV-2 cases in Madrid
- Author
-
Pérez-Lago L, Sola Campoy PJ, Buenestado-Serrano S, Catalán P, Estévez A, de la Cueva VM, López MG, Herranz M, Suárez-González J, Alcalá L, Comas I, Candelas FG, Muñoz P, and de Viedma DG
- Published
- 2021
46. Dos noves espècies del gènere Parvospeonomus Bellés & Escolà, 1977 (Coleoptera: Leiodidae: Leptodirini)
- Author
-
Comas i Angelet, Jordi and Comas i Angelet, Jordi
- Abstract
En el present treball, es descriuen dues noves espècies del gènere Parvospeonomus Bellés & Escolà, 1977, que han restat confoses amb Parvospeonomus urgellesi (Español, 1965): Parvospeonomus garrigai n. sp. i Parvospeonomus cruillensis n. sp., per la similitud de la seva morfologia dels habitus. Són mostrades imatges, de les diferències morfològiques entra les tres espècies estudiades., In the present work, two new species of the genus Parvospeonomus Bellés & Escolà, 1977 are described, which have been confused with Parvospeonomus urgellesi (Español, 1965): Parvospeonomus garrigai n. sp. and Parvospeonomus cruillensis n. sp., by the similarity of their morphology of habits. Images are shown, of the morphological differences between the three species studied.
- Published
- 2021
47. Un nou gènere i espècie de Molopina hipogeu del Pirineu Català (Alt Urgell, Lleida) (Coleoptera: Carabidae: Pterostichini)
- Author
-
Comas i Angelet, Jordi, Vives i Noguera, Eduard, Comas i Angelet, Jordi, and Vives i Noguera, Eduard
- Abstract
Es descriu un nou gènere i una i nova espècie hipogea de la subtribu Molopina (Coleoptera: Carabidae: Pterostichini). Speleopidius joanivivesi n. gen. & n. sp., procedent de l'Avenc de la Cabana d'en Garraba, Pont de Bar (L'Alt Urgell, Lleida, Espanya). Es compara la relació del nou gènere i nova espècie amb d'altres Molopina hipogeus de la mediterrània occidental., It is described a new genus and a new hypogean species of the subtribe Molopina, tribe Pterostichini (Coleoptera, Carabidae), namely Speleopidius joanivivesi n. gen. & n. sp., from the Avenc de la Cabana d'en Garraba, Pont de Bar (L'Alt Urgell), Lleida, Spain. The relationships of the new taxa with other hypogean Molopina of the Western Mediterranean are discussed.
- Published
- 2021
48. B‐type natriuretic peptide over N‐terminal pro‐brain natriuretic peptide to predict incident atrial fibrillation after cryptogenic stroke
- Author
-
Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (España), European Commission, Vall d'Hebron Research Institute, Red de Enfermedades Vasculares Cerebrales (España), Palà, Elena, Pagola, Jorge, Juega, Jesús, Francisco‐Pascual, Jaume, Bustamante, Alejandro, Penalba, Anna, Comas, I., Rodríguez, M., Lera Alfonso, Mercedes de, Arenillas, Juan F., Torres, Reyes de, Pérez-Sánchez, Soledad, Cabezas, Juan A., Moniche, Francisco, González-Alujas, Teresa, Molina, Carlos A., Montaner, Joan, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (España), European Commission, Vall d'Hebron Research Institute, Red de Enfermedades Vasculares Cerebrales (España), Palà, Elena, Pagola, Jorge, Juega, Jesús, Francisco‐Pascual, Jaume, Bustamante, Alejandro, Penalba, Anna, Comas, I., Rodríguez, M., Lera Alfonso, Mercedes de, Arenillas, Juan F., Torres, Reyes de, Pérez-Sánchez, Soledad, Cabezas, Juan A., Moniche, Francisco, González-Alujas, Teresa, Molina, Carlos A., and Montaner, Joan
- Abstract
[Background and purpose] B‐type natriuretic peptide (BNP) and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) are well‐known surrogates of atrial fibrillation (AF) detection but studies usually present data on either BNP or NT‐proBNP. The aim was to determine and directly compare the validity of the two biomarkers as a tool to predict AF and guide prolonged cardiac monitoring in cryptogenic stroke patients., [Methods] Non‐lacunar acute ischaemic stroke (<72 h) patients over 55 years of age with cryptogenic stroke after standard evaluation were included in the Crypto‐AF study and blood was collected. BNP and NT‐proBNP levels were determined by automated immunoassays. AF was assessed by 28 days’ monitoring. Highest (optimizing specificity) and lowest (optimizing sensitivity) quartiles were used as biomarker cut‐offs to build predictive models adjusted by sex and age. The integrated discrimination improvement index (IDI) and DeLong test were used to compare the performance of the two biomarkers., [Results] From 320 patients evaluated, 218 were included in the analysis. AF was detected in 50 patients (22.9%). NT‐proBNP (P < 0.001) and BNP (P < 0.001) levels were higher in subjects with AF and their levels correlated (r = 0.495, P < 0.001). BNP showed an increased area under the curve (0.720 vs. 0.669; P = 0.0218) and a better predictive capacity (IDI = 3.63%, 95% confidence interval 1.36%–5.91%) compared to NT‐proBNP. BNP performed better than NT‐proBNP in a specific model (IDI = 3.7%, 95% confidence interval 0.87%–6.5%), whilst both biomarkers performed similarly in the case of a sensitive model., [Conclusions] Both BNP and NT‐proBNP were increased in cryptogenic stroke patients with AF detection. Interestingly, BNP outperforms NT‐proBNP, especially in terms of specificity.
- Published
- 2021
49. Whole-genome sequencing for TB source investigations: principles of ethical precision public health
- Author
-
Van Rie, A., primary, de Viedma, D. G., additional, Meehan, C., additional, Comas, I., additional, Heupink, T. H., additional, De Vos, E., additional, de Oñate, W. A., additional, Mathys, V., additional, Ceyssens, P-J., additional, Groenen, G., additional, González‐Candelas, F., additional, Forier, A., additional, and Juengst, E., additional
- Published
- 2021
- Full Text
- View/download PDF
50. Fast and low-cost decentralized surveillance of transmission of tuberculosis based on strain-specific PCRs tailored from whole genome sequencing data: a pilot study
- Author
-
Pérez-Lago, L., Martínez Lirola, M., Herranz, M., Comas, I., Bouza, E., and García-de-Viedma, D.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.